[an error occurred while processing this directive]
NGS Oncology Assays
The AVENIO family of next-generation sequencing (NGS) oncology assays comprises three liquid biopsy assays and three new corresponding tissue assays with matched panel content. New AVENIO Tumor Tissue Analysis Kits, together with AVENIO ctDNA Analysis Kits, offer a uniquely versatile solution for comprehensive genomic profiling, longitudinal monitoring and concordance analysis of solid tumors from tissue and plasma samples.
Features and Benefits of AVENIO NGS Oncology Assays
Flexibility to switch between tissue and plasma to support a variety of research applications
Exactly-matched tissue and ctDNA panels (same genes, gene regions and hybrid-capture workflow) for true concordance
All four mutation classes (SNVs, indels, fusions and CNVs) in a single DNA workflow with exceptional sensitivity and specificity*
A streamlined, end-to-end workflow from extraction to analysis and reporting in 5 days
A turnkey solution that includes reagents, intuitive analysis and reporting to facilitate in-house adoption of high performance NGS oncology testing
All four mutation classes in a single DNA workflow
Potential research applications
AVENIO Kits contain gene panels with biomarkers relevant to clinical cancer research over the course of disease evolution.
AVENIO Tumor Tissue Analysis Kits
Three NGS pan-cancer assays for comprehensive genomic profiling of DNA in formalin-fixed paraffin-embedded (FFPE) tissue samples
AVENIO ctDNA Analysis Kits
Three NGS pan-cancer liquid biopsy assays for non-invasive profiling and monitoring of cell-free DNA derived from solid tumors
*Data on file.
Research Use Only. Not for use in diagnostic procedures.
AVENIO is a trademark of Roche. All other product names and trademarks are the property of their respective owners.
Found 0 results in
Some randomr randomr randomr randomr randomr randomr
To play the media you will need to either update your browser to a recent version or update your